Main article: Vision
Inherited retinal dystrophies are a group of inherited ophthalmic diseases that can be caused by mutations in more than 200 different genes. For 2023, a gene therapy drug has been registered in Russia for the treatment of a disease caused by mutations in the RPE65 gene. It makes it possible to completely stop the disease, death of the retina and significantly increase functional vision.
2023:35 patients identified in Russia
The target diagnostic program for inherited retinal dystrophies was launched at the Academician N.P. Bochkov Medical Genetic Scientific Center in 2021. As of February 2023, to the only Scientific and Clinical Center in Russia ophthalmogenetics of MHSC are applied by patients from all regions of Russia, as well as from neighboring states: Belarus, Kazakhstan, Uzbekistan. The diagnostic program applies to other regions. By this time, 35 patients had been identified.
2021: Susvimo Eye Implant Market Entry for Retinal Dystrophy
On October 22, 2021, Genentech announced the market launch of Susvimo eye implant for the treatment of retinal dystrophy. This is a chronic progressive disease of the posterior segment of the eye, characterized by dystrophic processes in the central retina and choroid of the eye. The implant is surgically inserted into the eye during a one-time outpatient procedure and replenished every next six months. Read more here.
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |